Background: Polypharmacy, potentially inappropriate medications and anticholinergic burden (as assessed by the anticholinergic risk scale) are commonly used as quality indicators of pharmacotherapy in older adults. However, their role in clinical practice is undefined. We sought to investigate longitudinal changes in these indicators and their effects on clinical outcomes.
P opulation aging is a global phenomenon that poses various health care challenges. With the expected increase in multi morbidity and associated high consumption of drugs among older adults, understanding the quality of drug use for this population is essen tial. Although several indicators have been developed to evaluate the quality of pharmaco therapy in older adults, such as polypharmacy, 1 potentially inappropriate medications 2, 3 and anticholinergic burden, 4 several questions remain as to their utility in clinical practice.
Empirical data are scarce regarding changes in drug use with the increasing burden of multi morbidities in a single patient. Most studies have examined these quality indicators in a cross sectional manner that provides onetime descriptive data 1, [5] [6] [7] [8] or in a repeated cross sectional manner that provides descriptive data over time. 9, 10 In a few prospective cohort stud ies an attempt was made to overcome the limi tations of crosssectional studies, but they were limited by small sample sizes or short follow up periods. 11, 12 Most of the previous studies have grouped people aged 65 years and older into a single age group. Empirical evidence regarding the poten tial variations in clinical conditions and treat ments, as well as their effects on drug use among older adults at different ages, is scarce, and dif ferences in drug use between older men and women have not been well investigated.
The available studies have shown inconclu sive findings in terms of the association between polypharmacy, potentially inappropriate medica tions or anticholinergic burden and possible adverse outcomes. [13] [14] [15] Some studies have shown that polypharmacy or potentially inappropriate medications are positively associated with admis sion to hospital or death, 13 while others have not. 15 Moreover, little is known regarding the ability to predict negative outcomes among poly pharmacy, potentially inappropriate medications or anticholinergic burden, because previous stud ies have focused on single indicators alone. [13] [14] [15] Our aim was to examine changes in polyphar macy, potentially inappropriate medications and anticholinergic burden over time among people aged 65 years and older. In addition, we sought to determine the association between changes in these indicators and clinical outcomes, specifi cally allcause admissions to hospital, fracture specific admissions to hospital and death.
Methods

Data source
We performed a populationbased retrospective cohort study using data from the National Health Insurance Research Database (NHIRD) -a nationwide claimbased database comprising anon ymous enrollment information and health care usage data for more than 99% of the population of Taiwan. 16 We used a subset of this database, the Longitudinal Health Insurance Database, which contains claims data for 1 million randomly selected beneficiaries from the NHIRD, to compose a 12year (2000-2011) panel of claims for analysis.
Because the identification numbers for all of the entries in the NHRID were encrypted to pro tect the privacy of the individual patients, this study was exempt from a full review by the Insti tutional Review Board of the National Taiwan University Hospital, and informed consent was waived (National Taiwan University Hospital Research Ethics Committee No. 201401004W).
Study cohort
We identified people who were more than 65 years old and placed them into 1 of 3 groups (65-74, 75-84 and ≥ 85 yr) based on their age at the time of enrollment (Jan. 1, 2001 ). We excluded people with diagnoses within 1 year before the date of recruitment of any of 22 chronic diseases requiring longterm medical care and support, such as cancer, rheumatoid arthritis or systemic lupus erythematosus under Taiwan's National Health Insurance system. We made these exclusions owing to patients' risk of death in the short term (Appendix 1, available at www.cmaj.ca /lookup/suppl/doi:10.1503 /cmaj .141219//DC1). The first year after recruitment served as the baseline informationgathering period. The followup period for each participant started on Jan. 1, 2002 , and ended on the date of death or on Dec. 31, 2011, whichever came first.
Outcome measures
During the 10year followup period, we retrieved data on drug use quarterly (Q1-Q40) from the out patient clinics in the Longitudinal Health Insurance Database. These data included prescribing dates, number of days' worth of drug supply and daily doses. We selected only those drugs with more than a 28day supply to determine polypharmacy, poten tially inappropriate medications or anticholinergic burden (as measured using the anticholinergic risk scale). All of the drugs were coded according to the World Health Organization (WHO) Anatomic Therapeutic Chemical classification system. 17 We defined polypharmacy and excessive poly pharmacy as the concomitant use of 5 or more and 10 or more drugs, respectively, based on previous studies. 7, 18 We defined potentially inappropriate medications using the 2012 update to the Ameri can Geriatrics Society's Beers Criteria.
2,3 These criteria include 53 medications (classes) divided into 3 categories: medications to avoid in older adults, medications to avoid in older adults with certain diseases and syndromes, and medications to be used with caution in older adults. 3 We focused on the 34 medications to avoid in older adults. We determined anticholinergic burden using the anticholinergic risk scale, 19 which ranks the 500 most frequently prescribed drugs with anticholinergic potential on a scale of 0-3 (0, lim ited or none; 1, moderate; 2, strong; 3, very strong potential) based on the dissociation constant for the muscarinic receptor and rates of adverse effects. A patient's score was the sum of the rank ings for all prescribed medications. 19 Our outcomes of interest were death, all cause admissions to hospital and fracture specific admissions to hospital (International Classification of Diseases, 9th revision, clinical modification diagnostic codes 800-829).
Other covariables
In addition to the age and sex of participants, we retrieved healthrelated information (such as the number of outpatient visits) and determined the Charlson comorbidity index 1 year before the date of entry to the cohort to serve as proxies of parti cipants' health statuses.
Statistical analysis
We used χ 2 tests to compare categorical vari ables and t tests or analyses of variance (ANOVA) to compare continuous variables. We used paired t tests to examine differences in polypharmacy, potentially inappropriate medica tions and anticholinergic risk scale scores (mean and 95% confidence intervals [CI] ) between the end of followup and the beginning.
Because the mean of differences in polyphar macy, potentially inappropriate medications and anticholinergic burden were not normally distrib uted, we used the Kruskal-Wallis and Wilcoxon ranksum tests to compare differences across age groups and sex.
We used the Chow test 17 to examine differ ences in the timevarying use of polypharmacy, potentially inappropriate medications or anticho linergic risk by age and sex.
We used generalized estimating equation (GEE) models with an autoregressive cor relation structure to examine the association between polypharmacy, potentially inappropri ate medications or anticholinergic risk and clin ical outcomes (i.e., death) that accounted for the intraclass correlation between repeated measurements for the same participants. We further adjusted these models for age, sex and timevarying comorbidities, but not for health related resource use owing to concern regarding the high collinearity between it and drug expo sure. We determined the likelihood of death or admission to hospital using a logit link with a binomial distribution (presented as the odds ratio [OR] with 95% CI). We performed all Over the 10year followup, the change in the number of drugs used was greatest among patients aged 65-74 yr (+2.14, 95% CI 2.10-2.19) ( Table  2 ). The number of potentially inappropriate medi cations used increased among patients aged 65-74 yr (+0.16 , 95% CI 0.15 to 0.18) and those aged 75-84 yr (+0.09, 95% CI 0.06 to 0.08), but decreased among those aged 85 years and older (-0.15, 95% CI -0.26 to -0.04). Anticholinergic risk increased in all age groups (p < 0.001), and the sizes of the changes in scores across groups were comparable (p = 0.4). We found a signifi cantly greater increase in the number of drugs used, number of potentially inappropriate medica tions and anticholinergic risk scores in men than in women among those aged 65-74 and 75-84 years ( Table 2 , Figures 1 and 2) . Changes over time in all 3 indicators of drug use varied by age and sex (p < 0.001), with the exception of anticholinergic risk in patients aged 65-74 v. 75-84 yr, p = 0.03).
We found a dose-response relation between polypharmacy and allcause admission to hospital (5-9 drugs: OR 1.34, 95% CI 1.32-1.36; ≥ 10 drugs: OR 1.98, 95% CI 1.94-2.03) ( Table 3) . Use of potentially inappropriate medications was asso ciated with a 27% increase in the risk of allcause admission to hospital (OR 1.27, 95% CI 1.25-1.28). Anticholinergic risk scores of 1-2 and 3 or more were associated with a 46% and 32% increase, respectively, in risk of allcause admis sion to hospital. Both polypharmacy (5-9 drugs: OR 1.18, 95% CI 1.12-1.24; ≥ 10 drugs: OR 1.54, 95% CI 1.42-1.66) and anticholinergic risk scale scores (1-2: OR 1.39, 95% CI 1.31-1.48; ≥ 3: OR 1.53, 95% CI 1.41-1.66) showed dose-response 
Interpretation
In this cohort of patients aged 65 years and older followed for 10 years, polypharmacy, potentially inappropriate medications and anti cholinergic burden changed over time and var ied across age groups and sex. We found good associations between these quality indicators of drug use and both allcause and fracturespecific admissions to hospital. By combining the results for our 3 age groups, we have presented the consumption of drugs 30 years after an initial age of 65 years (65-95 years old). Previous studies have addressed simi lar concepts, but have been limited by small sam ple sizes and short followup periods. 11, 20 In a ret rospective cohort study involving 1544 patients, Veehof 11 Thus, we add to the current literature owing to our use of a larger sample and extended followup period.
In addition, we documented changes over time in anticholinergic burden in communitydwelling older adults. Our results from patients aged 85 years and older suggest that physicians may be more likely to withhold treatments in this age group owing to limited life expectancy or high vulnerability to treatmentrelated adverse events. We found dose-response relations between polypharmacy or potentially inappropriate medi cations and allcause admission to hospital. How ever, Pozzi and colleagues reported that poten tially inappropriate medications (hazard ratio [HR] 1.03, 95% CI 1.00-1.06), but not polyphar macy (HR 0.77, 95% CI 0.58-1.01), were associ ated with admission to hospital. 15 This discrep ancy may result from the measurement of drug exposure. We measured drug use quarterly during followup and included changes in drug use in our models as timevarying variables, whereas Pozzi and colleagues used 2wave crosssectional mea surements of drug use at baseline to predict subse quent admissions to hospital. 15 Our results regarding dose-response relations between polypharmacy or potentially inappropri ate medications and fracturespecific admissions to hospital are in accordance with previous stud ies. 21, 22 Most of those studies focused on the link between anticholinergic burden and cognitive function;
12,23 thus, our study expands the potential use of anticholinergic risk scale by showing that a higher score was associated with a higher risk of admission to hospital. Some overlapping may have occurred in potentially inappropriate medications or anticholinergic burden. Koyama and colleagues reported that among communitydwelling women aged 75 years and older, the most frequently reported potentially inappropriate medications were anticholinergic agents (15.2%). In addition, Lee and colleagues reported that patients with 6-10 or 11 or more prescribed medications were significantly more likely to receive prescriptions for anticholinergic agents (OR 3.41, 95% CI 2.23-5.22 and OR 4.69, 95% CI 2.99-7.34, respec tively). 23 Therefore, because we found a similar ability to predict fracturespecific admissions to hospital with use of each of 10 or more drugs, potentially inappropriate medications and anticho linergic burden, polypharmacy may serve as a quick quality indicator of drug use in older adults.
The associations of these quality indicators with risk of death remain unclear. Espino and colleagues reported an increased risk of death associated with polypharmacy (HR 1.27, 95% CI 1.04-1.56) in a cohort study with an 8year followup period. 13 However, Pozzi and colleagues (HR 1.20, 95% CI 0.89-1.60) 15 and Jyrkkä and colleagues (polyphar macy HR 0.77, 95% CI 0.58-1.01; excessive poly pharmacy HR 1.28 95% CI 0.86-1.91) 1 reported no such association. Furthermore, Pozzi and col leagues suggested that potentially inappropriate medications were not associated with an increased risk of death (HR 1.00, 95% CI 0.96-1.06). 15 We found that polypharmacy (≥ 10 drugs), potentially inappropriate medications and elevated anticholin ergic burden were associated with a reduced risk of death. One explanation for this phenomenon is the high number of patients who spend their final days in hospitals in Taiwan, and the daily variation in their drug use owing to urgent conditions. Because we only identified drugs with a supply period of more than 28 days to measure our 3 quality indica tors, we were unable to capture endoflife drug use. Our results showed that patients using 10 or more medications, patients using potentially inap propriate medications and patients with high anti cholinergic burden were at a lower risk of death.
Limitations
Our use of numbers and amounts of medicine pre scribed to define exposure presumes that patients always take the medicines they have been given. In addition, because we relied on claims data, we were unable to include drugs that are not covered by National Health Insurance, such as overthe counter medications, herbal supplements and alternative remedies. Furthermore, we were not able to include variables that are not routinely captured in the claims database, such as tobacco or alcohol consumption. Finally, because the NHIRD only recorded up to 5 diagnoses per patient visit, 18 we may have underestimated the prevalence of comorbidities in our cohort.
Conclusion
Prescribing patterns among this group of older adult patients from Taiwan changed during the fol lowup period and varied across age groups and sex. We found dose-response relations between all 3 indicators of quality of drug use (polypharmacy, use of potentially inappropriate medications and anticholinergic burden) and admission to hospital (allcause and fracture specific), but not death. These findings are relevant to both clinicians and policymakers, because a reevaluation of the role of polypharmacy, potentially inappropriate medi cations and anticholinergic burden in older adults may be warranted.
